초록 ▼

Viral infections are treated by the administration of alpha-interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The IFN-.alpha. is administered in a solid dosage from, e.g., a saliva-dissolvable l

Viral infections are treated by the administration of alpha-interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The IFN-.alpha. is administered in a solid dosage from, e.g., a saliva-dissolvable lozenge.

대표청구항 ▼

[ I claim:] [1.] A method of treatment of a human patient afflicted with a disease of viral origin using interferon to stimulate an anti-viral response, the method consisting essentially of the steps ofselecting a saliva-soluble solid dosage form of human alpha-interferon,introducing the solid dosag

[ I claim:] [1.] A method of treatment of a human patient afflicted with a disease of viral origin using interferon to stimulate an anti-viral response, the method consisting essentially of the steps ofselecting a saliva-soluble solid dosage form of human alpha-interferon,introducing the solid dosage form of interferon into the mouth of the patient,holding the solid dosage form in the patient's mouth for a period of time sufficient to dissolve it and form a saliva solution of the interferon in contact with the patient's oral and pharyngeal mucosa and stimulate an anti-viral response,wherein the interferon is administered to the patient in an amount of about 0.01 to about 5.0 IU of human alpha-interferon per lb of body weight per day.